125 related articles for article (PubMed ID: 21568730)
1. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes.
Mojtahedi Z; Safaei A; Yousefi Z; Ghaderi A
OMICS; 2011 Jun; 15(6):409-18. PubMed ID: 21568730
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA).
Hamrita B; Chahed K; Kabbage M; Guillier CL; Trimeche M; Chaïeb A; Chouchane L
Clin Chim Acta; 2008 Jul; 393(2):95-102. PubMed ID: 18424265
[TBL] [Abstract][Full Text] [Related]
3. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis.
Tamesa MS; Kuramitsu Y; Fujimoto M; Maeda N; Nagashima Y; Tanaka T; Yamamoto S; Oka M; Nakamura K
Electrophoresis; 2009 Jun; 30(12):2168-81. PubMed ID: 19582718
[TBL] [Abstract][Full Text] [Related]
4. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.
Bailur JK; Gueckel B; Derhovanessian E; Pawelec G
Breast Cancer Res; 2015 Mar; 17(1):34. PubMed ID: 25849846
[TBL] [Abstract][Full Text] [Related]
5. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer.
Auvinen P; Tammi R; Kosma VM; Sironen R; Soini Y; Mannermaa A; Tumelius R; Uljas E; Tammi M
Int J Cancer; 2013 Feb; 132(3):531-9. PubMed ID: 22753277
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion.
Milioli HH; Santos Sousa K; Kaviski R; Dos Santos Oliveira NC; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM
Cancer Genomics Proteomics; 2015; 12(2):89-101. PubMed ID: 25770193
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
8. An efficient proteomics-based approach for the screening of autoantibodies.
Canelle L; Bousquet J; Pionneau C; Deneux L; Imam-Sghiouar N; Caron M; Joubert-Caron R
J Immunol Methods; 2005 Apr; 299(1-2):77-89. PubMed ID: 15914192
[TBL] [Abstract][Full Text] [Related]
9. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer.
Le Naour F; Misek DE; Krause MC; Deneux L; Giordano TJ; Scholl S; Hanash SM
Clin Cancer Res; 2001 Nov; 7(11):3328-35. PubMed ID: 11705844
[TBL] [Abstract][Full Text] [Related]
10. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
12. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.
Hu X; Zhang Y; Zhang A; Li Y; Zhu Z; Shao Z; Zeng R; Xu LX
OMICS; 2009 Aug; 13(4):291-300. PubMed ID: 19624269
[TBL] [Abstract][Full Text] [Related]
13. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers.
Pendharkar N; Gajbhiye A; Taunk K; RoyChoudhury S; Dhali S; Seal S; Mane A; Abhang S; Santra MK; Chaudhury K; Rapole S
J Proteomics; 2016 Jan; 132():112-30. PubMed ID: 26642762
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
15. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients.
Suzuki E; Kataoka TR; Hirata M; Kawaguchi K; Nishie M; Haga H; Toi M
BMC Cancer; 2015 Feb; 15():39. PubMed ID: 25655677
[TBL] [Abstract][Full Text] [Related]
16. Differential protein expression in primary breast cancer and matched axillary node metastasis.
Thongwatchara P; Promwikorn W; Srisomsap C; Chokchaichamnankit D; Boonyaphiphat P; Thongsuksai P
Oncol Rep; 2011 Jul; 26(1):185-91. PubMed ID: 21503584
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
[TBL] [Abstract][Full Text] [Related]
18. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
[TBL] [Abstract][Full Text] [Related]
19. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
20. Negative estrogen-receptor invasive breast carcinoma: mammographic aspects, correlations with HER2/neu oncoprotein status.
Enache DE; Georgescu CV; Pătrană N
Rom J Morphol Embryol; 2012; 53(3 Suppl):755-62. PubMed ID: 23188436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
